A Phase 4, Randomized, Open Label, Parallel Group, Multicenter Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin or Rapid Acting Insulin in Patients With Type 2 Diabetes.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Pramlintide (Primary) ; Insulin aspart; Insulin detemir; Insulin glargine; Insulin glulisine; Insulin lispro; Insulins
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms INSTEAD
- Sponsors Amylin Pharmaceuticals
- 03 Mar 2010 Treatment satisfaction and quality-of-life effects published in Current Medical Research and Opinion.
- 29 Sep 2009 Results have been presented at EASD 2009.
- 01 Sep 2009 Results published in Diabetes Care.